Drug Trial Radar · NCT02914509
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
Last checked: Nov 19, 2026Latest source record: Oct 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
565
Actual
Start
Nov 7, 2016
Primary completion
Mar 30, 2019
Study completion Mar 30, 2019
Sponsor
- Lead sponsor
- Ocular Therapeutix, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension
Conditions
- Open Angle Glaucoma
- Ocular Hypertension
Interventions
TravoprostDrug
Placebo VehicleOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean IOPTime frame: Mean IOP at 8AM, 10AM, and 4PM at the 2 Week Visit
- Mean IOPTime frame: Mean IOP at 8AM, 10AM, and 4PM at the 6 Week Visit
- Mean IOPTime frame: Mean IOP at 8AM, 10AM, and 4PM at the 12 Week Visit
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Artesia, California
Site not named
Colorado Springs, Colorado
Site not named
Lakeland, Florida
Site not named
Morrow, Georgia
Site not named
Shawnee Mission, Kansas
Site not named
Des Peres, Missouri
Site not named
Rochester, New York
Site not named
Raleigh, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.